<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Evid Based Complement Alternat Med</journal-id><journal-id journal-id-type="iso-abbrev">Evid Based Complement Alternat Med</journal-id><journal-id journal-id-type="publisher-id">ECAM</journal-id><journal-title-group><journal-title>Evidence-based Complementary and Alternative Medicine : eCAM</journal-title></journal-title-group><issn pub-type="ppub">1741-427X</issn><issn pub-type="epub">1741-4288</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26074982</article-id><article-id pub-id-type="pmc">4449914</article-id><article-id pub-id-type="doi">10.1155/2015/101904</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Wenxin Keli versus Sotalol for Paroxysmal Atrial Fibrillation Caused by Hyperthyroidism: A Prospective, Open Label, and Randomized Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Meng</surname><given-names>Zhaowei</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Tan</surname><given-names>Jian</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor2">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>He</surname><given-names>Qing</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Mei</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Xue</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Jianping</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Jia</surname><given-names>Qiang</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Shen</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Guizhi</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Department of Nuclear Medicine, Tianjin Medical University General Hospital, Anshan Road No. 154, Heping District, Tianjin 300052, China</aff><aff id="I2"><sup>2</sup>Department of Endocrinology, Tianjin Medical University General Hospital, Tianjin 300052, China</aff><author-notes><corresp id="cor1">*Zhaowei Meng: <email>jamesmencius@163.com</email> and </corresp><corresp id="cor2">*Jian Tan: <email>tanposta@163.com</email></corresp><fn fn-type="other"><p>Academic Editor: Myeong Soo Lee</p></fn></author-notes><pub-date pub-type="ppub"><year>2015</year></pub-date><pub-date pub-type="epub"><day>17</day><month>5</month><year>2015</year></pub-date><volume>2015</volume><elocation-id>101904</elocation-id><history><date date-type="received"><day>27</day><month>6</month><year>2014</year></date><date date-type="rev-recd"><day>5</day><month>10</month><year>2014</year></date><date date-type="accepted"><day>12</day><month>10</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2015 Zhaowei Meng et al.</copyright-statement><copyright-year>2015</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>We aimed to compare effectiveness of Wenxin Keli (WK) and sotalol in assisting sinus rhythm (SR) restoration from paroxysmal atrial fibrillation (PAF) caused by hyperthyroidism, as well as in maintaining SR. We randomly prescribed WK (18&#x02009;g tid) or sotalol (80&#x02009;mg bid) to 91 or 89 patients. Since it was not ethical not to give patients antiarrhythmia drugs, no control group was set. Antithyroid drugs were given to 90 patients (45 in WK group, 45 in sotalol group); <sup>131</sup>I was given to 90 patients (46 in WK group, 44 in sotalol group). Three months later, SR was obtained in 83/91 or 80/89 cases from WK or sotalol groups (<italic>P</italic> = 0.762). By another analysis, SR was obtained in 86/90 or 77/90 cases from <sup>131</sup>I or ATD groups (<italic>P</italic> = 0.022). Then, we randomly assigned the successfully SR-reverted patients into three groups: WK, sotalol, and control (no antiarrhythmia drug was given) groups. After twelve-month follow-up, PAF recurrence happened in 1/54, 2/54, and 9/55 cases, respectively. Log-Rank test showed significant higher PAF recurrent rate in control patients than either treatment (<italic>P</italic> = 0.06). We demonstrated the same efficacies of WK and sotalol to assist SR reversion from hyperthyroidism-caused PAF. We also showed that either drug could maintain SR in such patients.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Atrial fibrillation is the most common cardiac rhythm disturbance, increasing in prevalence with age. By definition, atrial fibrillation is a supraventricular tachyarrhythmia characterized by uncoordinated atrial activation with consequent deterioration of atrial mechanical function [<xref rid="B1" ref-type="bibr">1</xref>&#x02013;<xref rid="B3" ref-type="bibr">3</xref>]. Clinicians should distinguish a first-detected episode of atrial fibrillation, whether or not it is symptomatic or self-limited. Patients with atrial fibrillation have markedly reduced survival rate compared with subjects without atrial fibrillation. In paroxysmal atrial fibrillation (PAF), sudden repeated changes in rhythm cause symptoms which most patients find very debilitating. In addition, PAF carries an increasing risk of thromboembolic events, when compared with chronic atrial fibrillation [<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>]. Therefore, the effective treatment and prevention of this kind of arrhythmia has important clinical significance [<xref rid="B1" ref-type="bibr">1</xref>&#x02013;<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>]. Atrial fibrillation occurs in 10% to 25% of patients with hyperthyroidism, more commonly in men and elderly patients [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>]. Mainstay treatment is restoration of euthyroid state, which can be accomplished by antithyroid drugs, <sup>131</sup>I, and surgery. Successful management of hyperthyroidism could result in restoration of sinus rhythm (SR) in up to two-thirds of patients [<xref rid="B10" ref-type="bibr">10</xref>]. Mechanism of hyperthyroidism-induced atrial fibrillation has been proposed [<xref rid="B10" ref-type="bibr">10</xref>&#x02013;<xref rid="B12" ref-type="bibr">12</xref>]. It is generally agreed that shortening of action potential duration and effective refractory period play key roles in this electrophysiological abnormality.</p><p>Wenxin Keli (WK) is a pure Chinese herb medicine. It has been reported to be useful in the treatment of atrial fibrillation [<xref rid="B13" ref-type="bibr">13</xref>&#x02013;<xref rid="B15" ref-type="bibr">15</xref>], ventricular arrhythmia [<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>], myocardial infarction-induced arrhythmia, heart failure, Brugada syndrome [<xref rid="B20" ref-type="bibr">18</xref>], and so forth. WK extract is composed of 5 components:<italic> Nardostachys chinensis</italic> Batal. extract (NcBe),<italic> Codonopsis</italic>, notoginseng, amber, and rhizoma polygonati. Burashnikov and colleagues [<xref rid="B13" ref-type="bibr">13</xref>] recently presented a fascinating electrophysiological investigation of WK on atrial fibrillation. This study showed that WK, as a novel atrial-selective sodium-channel blocking agent, could prolong action potential duration and effective refractory period. This investigation was hailed in the same issue's editorial commentary as an emblematic milestone of integrating traditional Chinese medicine into Western medical practices [<xref rid="B14" ref-type="bibr">14</xref>]. In fact, WK monotherapy or in a combined antiarrhythmic regimen has been widely used for arrhythmia management in China. Chen and colleagues [<xref rid="B15" ref-type="bibr">15</xref>] recently conducted a meta-analysis and found solid evidence to prove WK as an effective drug to improve P-wave dispersion as well as to maintain SR in patients with PAF and its complications. However, the effect of WK on hyperthyroidism-induced atrial fibrillation has never been studied so far.</p><p>Therefore, in this open label and randomized study, we aimed to prospectively compare the effectiveness between WK and sotalol in assisting SR reversion from hyperthyroidism-caused PAF. We also intended to study their effectiveness in the maintenance of SR. Sotalol was chosen as a comparing drug, because it was proven to have efficacy to restore and maintain SR from atrial fibrillation. And sotalol possessed both class II and class III antiarrhythmic effects [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>].</p></sec><sec id="sec2"><title>2. Patients and Methods</title><sec id="sec2.1"><title>2.1. Patients</title><p>From January 2011 till January 2013, a series of 180 hyperthyroidism patients (diagnosed as Graves' disease), who came to either Nuclear Medicine Department or Endocrinology Department, were consecutively enrolled in this prospective study. All of the patients had symptomatic PAF. There were 98 males (55.48 &#x000b1; 12.02 years old) and 82 females (56.12 &#x000b1; 9.98 years old). Entry criteria included PAF due to hyperthyroidism; electrocardiographic evidence of atrial fibrillation; symptoms such as palpitations, light headedness, chest pain, and dyspnoea in association with PAF; good compliance. Exclusion criteria were PAF due to other reasons, recent myocardial infarction, heart failure, inflammation such as pneumonia and diarrhea, unstable hepatic or renal function, poor compliance, and other major medical problems that would leave the patient with a life expectancy of less than two years. All enrolled patients gave their informed consent. This study was approved by the Institutional Review Board of Tianjin Medical University General Hospital (approval number #20101207A).</p></sec><sec id="sec2.2"><title>2.2. Definition</title><p>The diagnosis of PAF was made according to the American College of Cardiology Foundation/American Heart Association Task Force guideline definition; briefly, PAF had episodes that were generally less than 7 days (most less than 24&#x02009;h), yet it was usually recurrent [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>].</p></sec><sec id="sec2.3"><title>2.3. Protocol</title><p>This study was designed as a prospective, open label, and randomized investigation. Generally, patients eligible for the study were allocated to one of the treatments using a computer generated random number algorithm. As reported [<xref rid="B15" ref-type="bibr">15</xref>], the clinical applications of WK against PAF include two aspects: restoration of SR from PAF and maintenance of SR afterwards. Therefore, we divided our study into two stages of sinus restoration and maintenance, in order to determine WK's effects on these two aspects.</p><p>Initially, baseline demographic data were obtained from the subjects. Relevant symptoms, cardiac diagnoses, and medical history were noted. Physical examination, 24-hour ambulatory electrocardiograph and/or regular 12-lead electrocardiograph, and serum biochemical tests (including electrolytes and renal and liver function) were carried out. All electrocardiographic recordings were reviewed by at least two experienced observers.</p><p>In the first part of the study, we randomly prescribed WK (18&#x02009;g tid) or sotalol (80&#x02009;mg bid) to 91 patients (49 males, 42 females) or 89 patients (49 males, 40 females), respectively. This part of the study compared the effectiveness of WK and sotalol to restore SR from PAF. In this investigation, it was not ethical not to give the patients any antiarrhythmia drugs. So, we did not design control; we just compared WK and sotalol. Antithyroid drugs (ATD) were given to 90 patients (45 in WK group, 45 in sotalol group), and <sup>131</sup>I was also given to 90 patients (46 in WK group, 44 in sotalol group). Due to the similar ethical reason, no control group was set. ATD-treated patients were given methimazole (initial dose 30&#x02009;mg per day). <sup>131</sup>I therapeutic procedure was performed according to our protocol [<xref rid="B21" ref-type="bibr">19</xref>, <xref rid="B22" ref-type="bibr">20</xref>]. Thyroid radioiodine uptake value was measured at 6, 24, 48, and 72 hours after an oral tracer dose uptake of <sup>131</sup>I (about 74&#x02009;kBq) by a nuclear multifunctional instrument (MN-6300XT Apparatus, Technological University, China). Then <sup>131</sup>I effective half-life time (<italic>T</italic>
<sub>1/2eff</sub>) and maximum uptake in thyroid were calculated. Thyroid ultrasonography was performed by using a color doppler ultrasound machine (GE Vingmed Ultrasound Vivid Five, Horten, Norway). Thyroid volume was calculated with the following formula: volume (cm<sup>3</sup>) = (width &#x000d7; length &#x000d7; thickness of left lobe) + (width &#x000d7; length &#x000d7; thickness of right lobe). Thyroid weight (g) = 0.479 &#x000d7; volume (cm<sup>3</sup>). Serum thyroid hormones were tested by an immunofluorometric assay, including free triiodothyronine (FT3, reference 3.50&#x02013;6.50&#x02009;pmol/L), free thyroxine (FT4, reference 11.50&#x02013;23.50&#x02009;pmol/L), and thyroid stimulating hormone (TSH, reference 0.20&#x02013;5.00&#x02009;<italic>&#x003bc;</italic>IU/mL). The therapeutic dose of <sup>131</sup>I was calculated as the following formula [<xref rid="B21" ref-type="bibr">19</xref>, <xref rid="B22" ref-type="bibr">20</xref>]: dose (37&#x02009;MBq) = (thyroid weight (g) &#x000d7; absorption dose (Gy/g) &#x000d7; 0.67)/(<italic>T</italic>
<sub>1/2eff</sub> (days) &#x000d7; maximum uptake (%)). Absorption dose = 100&#x02009;Gy/g thyroid tissue; 0.67 is a rectified factor. Participants visited our outpatient department every month. At each scheduled follow-up visit, physical examination and routine laboratory tests were done. And, at the end of the third month, ambulatory electrocardiograph and/or regular 12-lead electrocardiograph were repeated; all relevant symptoms were documented. Disappearing of PAF was defined as restoration of SR.</p><p>In the second part of the study, we randomly assigned the successfully SR-reverted patients into one of the following three groups: 54 cases were given WK (9&#x02009;g tid), 54 cases were given sotalol (40&#x02009;mg bid), and 55 cases served as control. In this part of the study, the control patients did not take any antiarrhythmia drug. Since patients recruited at this stage had much better improved thyroid status, and all of them were in SR when entering this investigation, it was ethically approved by our Institutional Review Board not to give the control patients any antiarrhythmia drugs. If patients were still in hyperthyroidism status, appropriate dose of methimazole was given to maintain euthyroidism. If the patients were in posttherapeutic hypothyroidism status, appropriate dose of levothyroxine was given to maintain euthyroidism. For hypothyroid patients who had already restored SR, WK and sotalol were stopped. Participants were asked to visit our outpatient department every three months. At each scheduled or sometimes unscheduled follow-up visit, physical examination and routine laboratory tests were repeated. And, at the end of the twelfth month, ambulatory electrocardiograph and/or regular 12-lead electrocardiograph were done; all relevant symptoms were documented. Time-point of PAF recurrence, its frequency, and related symptoms were collected as well.</p><p>Participant flow chart was presented in <xref ref-type="fig" rid="fig1">Figure 1</xref> to illustrate the whole study process for better understanding.</p></sec><sec id="sec2.4"><title>2.4. Statistical Analysis</title><p>All data were presented as mean &#x000b1; SD. Statistics were performed with SPSS 17.0 (SPSS Incorporated, IL, USA). Differences between two groups were analyzed by independent samples <italic>t</italic>-test. Differences between multiple groups were analyzed by one-way analysis of variance (ANOVA), and then least significant difference (LSD) test was used for multiple comparisons among the groups.&#x02009; <italic>&#x003c7;</italic>
<sup><italic>2</italic></sup> test was adopted to determine case number changes of patients after different treatments. &#x02009;<italic>&#x003c7;</italic>
<sup><italic>2</italic></sup> test was also used to check whether sex had a significant influence on the intergroup differences. Kaplan-Meier analysis by Log-Rank&#x02009;<italic>&#x003c7;</italic>
<sup><italic>2</italic></sup> test was used to estimate the cumulative recurrent rate of PAF in different groups.<italic> P</italic> value not exceeding 0.05 was considered statistically significant.</p></sec></sec><sec id="sec3"><title>3. Results</title><sec id="sec3.1"><title>3.1. Sinus Rhythm Restoration by Different Therapies</title><p>First, baseline information revealed no significant differences of hyperthyroidism history, PAF history, or thyroid hormone levels between the groups (<xref ref-type="table" rid="tab1">Table 1</xref>). Data in this investigation were analyzed by two ways. In the first analysis, three months after treatment of WK or sotalol, SR was obtained in 83/91 cases (91.209%) or 80/89 cases (89.888%);&#x02009;<italic>&#x003c7;</italic>
<sup><italic>2</italic></sup> test showed no significant differences, indicating equal efficacies of the two drugs for assisting SR reversion (<xref ref-type="table" rid="tab2">Table 2</xref>). Sex did not cause significant differences between the groups (<xref ref-type="table" rid="tab2">Table 2</xref>). Thyroid hormones also demonstrated no differences before or after treatments (<xref ref-type="table" rid="tab3">Table 3</xref>). In the second analysis, after treatment of <sup>131</sup>I or ATD, SR was obtained in 86/90 cases or 77/90 cases;&#x02009;<italic>&#x003c7;</italic>
<sup><italic>2</italic></sup> test showed significant differences, indicating better effects of <sup>131</sup>I treatment (<xref ref-type="table" rid="tab4">Table 4</xref>). Thyroid hormones displayed no differences before treatment, yet significant differences existed after treatment (<xref ref-type="table" rid="tab5">Table 5</xref>). A typical case showing successful converted SR from PAF was presented (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p></sec><sec id="sec3.2"><title>3.2. Sinus Rhythm Maintenance by Different Therapies</title><p>Data in the second investigation were analyzed by two methods. First, at the end of twelve-month follow-up, recurrent PAF happened in 1/54 (1.852%), 2/54 (3.704%), and 9/55 (16.364%) cases in WK, sotalol, or control groups, respectively. We found no differences of thyroid hormones at any follow-up time-point among the groups (<xref ref-type="table" rid="tab6">Table 6</xref>). However,&#x02009;<italic>&#x003c7;</italic>
<sup><italic>2</italic></sup> test showed significant differences between WK and control groups and significant differences between sotalol and control groups, while there were no differences between WK and sotalol groups (<xref ref-type="table" rid="tab7">Table 7</xref>). Second, Kaplan-Meier curves were drawn to determine the cumulative recurrent rate of PAF in different groups (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Log-Rank test showed significant higher PAF recurrent rate in control patients compared with either treatment (<italic>&#x003c7;</italic>
<sup>2</sup> = 10.229, <italic>P</italic> = 0.06). Therefore, we proved that both WK and sotalol could successfully maintain SR.</p></sec><sec id="sec3.3"><title>3.3. Side Effects</title><p>Since there is always an inherent bitter taste in Chinese medicine, some patients would unavoidably complain about the gastrointestinal discomfort or related symptoms after taking WK. Altogether, there were 10/91 cases (10.989%) in the first investigation and 6/54 (11.111%) in the second investigation who reported various degrees of nausea and dizziness after taking WK. However, all patients showed endurance and continued with the medication. For sotalol groups, the gastrointestinal discomfort was far less frequent; there were only 3/89 cases (3.371%) in the first investigation and 2/54 (3.704%) in the second investigation who reported mild stomach discomfort. However, after taking sotalol, 2/89 cases (2.247%) in the first investigation developed symptomatic bradycardia, whose PAF disappeared though. The problems completely dissolved after dose reduction from 80&#x02009;mg bid to 40&#x02009;mg bid for one patient and from 80&#x02009;mg bid to 40&#x02009;mg&#x02009;qd for the other patient. These two patients' heart rhythm maintained SR during the rest of the study. WK showed no bradycardia side effect. No other unwanted incidences were recorded.</p></sec></sec><sec id="sec4"><title>4. Discussion</title><p>The risk of developing atrial fibrillation in patients with hyperthyroidism is approximately 6-fold of the euthyroidism population, which aggravates the overall conditions of such patients [<xref rid="B9" ref-type="bibr">9</xref>]. Successful treatment of hyperthyroidism with either <sup>131</sup>I or ATD is associated with a reversion to SR in a majority of patients [<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B23" ref-type="bibr">21</xref>, <xref rid="B24" ref-type="bibr">22</xref>]. However, pharmacological management of atrial fibrillation in patients with hyperthyroidism is still an issue lacking in comprehensive analysis. In general, rate control is very important to reduce the mortality rate of patients with atrial fibrillation [<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>]. Selective or nonselective <italic>&#x003b2;</italic>-blockers can provide rapid symptom relief by reducing the ventricular rate, but these agents are unlikely to convert PAF to SR. Pharmacotherapy of atrial fibrillation has an advantage over electrical cardioversion and the catheter ablation methods, because it can be used on an outpatient basis [<xref rid="B25" ref-type="bibr">23</xref>]. However, the optimal pharmacological means to restore and maintain SR in patients with hyperthyroidism-caused atrial fibrillation remains controversial.</p><p>WK is identified as a novel drug against atrial fibrillation. Its mechanism has been elucidated recently. Burashnikov and colleagues [<xref rid="B13" ref-type="bibr">13</xref>] have implemented an isolated canine perfused right atrial preparation and recorded atrial and ventricular transmembrane action potentials and pseudoelectrograms before and after intracoronary perfusion of various concentrations of WK. Interestingly, WK produced effects more noticeable in atrial tissue than in ventricular tissue, as it caused action potential duration shortening and prolongation of effective refractory periods in an atrial-selective manner. In addition, WK produced a greater reduction in the maximum rate of rise of the action potential upstroke and a larger increase in the diastolic threshold for excitation in atrial cells, suggestive of sodium-channel current blockade. This was confirmed in HEK293 cells expressing the sodium ion channel protein SCN5A, in which WK decreased the peak sodium-channel current, in both dose-dependent and use-dependent fashions. Finally, antiarrhythmic properties of WK were illustrated by the prolongation of the P-wave duration and both the prevention and termination of acetylcholine-mediated atrial fibrillation. The above mechanism of WK acts directly against the electrophysiological changes in hyperthyroidism-induced atrial fibrillation [<xref rid="B10" ref-type="bibr">10</xref>&#x02013;<xref rid="B12" ref-type="bibr">12</xref>].</p><p>Contrary to the relatively new discovery of the MK mechanisms, traditional Chinese medicines were first documented about 2500 years ago by Confucian scholars and are now still being used by tens of millions in China as well as around the world [<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B26" ref-type="bibr">24</xref>, <xref rid="B27" ref-type="bibr">25</xref>]. Clinical evidence of WK is based on results of clinical trials being carried out in Chinese hospitals for years. These studies have shown that WK can significantly improve heart palpitations, chest tightness, shortness of breath, fatigue, insomnia, and other symptoms of atrial fibrillation [<xref rid="B15" ref-type="bibr">15</xref>]. Currently, WK monotherapy or combined therapy with antiarrhythmic drugs has been recommended as an effective method for atrial fibrillation in China. In fact, WK is the first Chinese-developed antiarrhythmic medicine to be approved by the Chinese state. Besides antiarrhythmic property, clinical trials have also confirmed that WK can increase coronary blood low, reduce myocardial oxygen consumption, enhance myocardial compliance, improve myocardial hypoxia tolerance, relieve anterior and posterior cardiac loading, and reduce myocardial tissue damage in patients with high blood pressure. These clinical evidences are in accordance with WK's basic mechanistic research findings recently [<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B16" ref-type="bibr">16</xref>&#x02013;<xref rid="B20" ref-type="bibr">18</xref>].</p><p>In the current investigation, we provided the first clinical evidence of WK as well as sotalol on the management of hyperthyroidism-induced PAF in two aspects. First, the drugs could assist SR reversion from PAF caused by hyperthyroidism. Second, the drugs could maintain SR afterwards. The second application seemed more important, since the first application was very dependent on the degree of thyroid hormone reduction. We showed that there were nearly the same efficacies of both WK and sotalol to assist SR restoration. However, <sup>131</sup>I was much more effective for hyperthyroidism management and thereafter to gain better SR reversion. We believed that this was largely due to better therapeutic results of <sup>131</sup>I to control thyroid hormones (Tables <xref ref-type="table" rid="tab4">4</xref> and <xref ref-type="table" rid="tab5">5</xref>). In the latter investigation, we showed that both WK and sotalol could maintain SR with equal abilities in our cohort, who have already gained SR after treatments. The cumulative recurrent rate was significantly lower in the drug-treated patients than in the control cases (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Our study proved the usefulness and effectiveness of WK as well as sotalol on the long-term maintenance management of such patients, which is indeed very important for clinical purposes.</p><p>Although WK's effect on hyperthyroidism-related atrial fibrillation has never been reported before, WK's anti-atrial-fibrillation ability is not new discovery. All of WK's clinical studies are published in Chinese language so far; however, after considering their relevancy to the current study, further comments are deserved. Chen and colleagues [<xref rid="B15" ref-type="bibr">15</xref>] compiled and evaluated all available randomized controlled trials regarding WK's therapeutic effects against PAF (complicated with diseases other than hyperthyroidism) according to the PRISMA systematic review standard. There were nine trials analyzing therapeutic effectiveness of WK alone or combined with Western medicine, compared with no medicine or Western medicine alone, in patients with PAF [<xref rid="B28" ref-type="bibr">26</xref>&#x02013;<xref rid="B36" ref-type="bibr">34</xref>]. Most of the trials used amiodarone as the Western medicine, which cannot be used for hyperthyroidism-related atrial fibrillation. These trials were not homogeneous, requiring the use of the random effects model for statistical analysis. Meta-analysis results demonstrated a significant difference between the two therapeutic groups (the WK combination therapy was much better). Seven trials used the maintenance rate of SR at six months following treatment as an outcome measurement [<xref rid="B35" ref-type="bibr">33</xref>&#x02013;<xref rid="B41" ref-type="bibr">39</xref>]. These seven trials compared the combination of WK plus Western medicine with Western medicine alone (mostly amiodarone). These trials were homogeneous, requiring the use of the fixed effects model for statistical analysis. The rate of maintenance of SR in the former group was greater than the latter group. Meta-analysis results showed that there was a significant beneficial effect in the WK combination regimens compared with the Western medicine monotherapy. The above literature is in conformity with our findings in that WK is an effective drug for the management of PAF, not only for initial SR reversion therapy but also for the long-term maintenance therapy.</p><p>In conclusion, we demonstrated the same efficacies of WK and sotalol to assist SR reversion from hyperthyroidism-related PAF. <sup>131</sup>I was better to control thyroid hormone and to gain SR reversion. We also showed that both WK and sotalol could maintain SR with equal abilities in those PAF hyperthyroidism patients who had already gained SR after treatments. Therefore, WK is a useful drug that should be advocated in the initial treatment of PAF caused by hyperthyroidism, as well as in the follow-up management strategy.</p></sec></body><back><ack><title>Acknowledgments </title><p>This investigation was supported by the National Key Clinical Specialty Project (awarded to the Departments of Nuclear Medicine and Radiology). This study was also supported by Tianjin Medical University New Century Excellent Talent Program, Young and Middle-aged Innovative Talent Training Program from Tianjin Education Committee, and Talent Fostering Program (the 131 Project) from Tianjin Human Resources and Social Security Bureau (awarded to Zhaowei Meng). The authors wish to thank Buchang Pharma Co. Ltd. for providing the drug of Wenxin Keli.</p></ack><sec sec-type="conflict"><title>Conflict of Interests</title><p>The authors declare that there is no conflict of interests regarding the publication of this paper.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wann</surname><given-names>L. S.</given-names></name><name><surname>Curtis</surname><given-names>A. B.</given-names></name><name><surname>January</surname><given-names>C. T.</given-names></name><etal/></person-group><article-title>2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</article-title><source><italic>Journal of the American College of Cardiology</italic></source><year>2011</year><volume>57</volume><issue>2</issue><fpage>223</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2010.10.001</pub-id><pub-id pub-id-type="pmid">21177058</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuster</surname><given-names>V.</given-names></name><name><surname>Ryd&#x000e9;n</surname><given-names>L. E.</given-names></name><name><surname>Cannom</surname><given-names>D. S.</given-names></name><etal/></person-group><article-title>2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society</article-title><source><italic>Journal of the American College of Cardiology</italic></source><year>2011</year><volume>57</volume><issue>11</issue><fpage>e101</fpage><lpage>e198</lpage><pub-id pub-id-type="other">2-s2.0-79955933219</pub-id><pub-id pub-id-type="pmid">21392637</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lip</surname><given-names>G. Y.</given-names></name><name><surname>Tse</surname><given-names>H.-F.</given-names></name></person-group><article-title>Management of atrial fibrillation</article-title><source><italic>The Lancet</italic></source><year>2007</year><volume>370</volume><issue>9587</issue><fpage>604</fpage><lpage>618</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(07)61300-2</pub-id><pub-id pub-id-type="other">2-s2.0-34248151980</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steeds</surname><given-names>R. P.</given-names></name><name><surname>Birchall</surname><given-names>A. S.</given-names></name><name><surname>Smith</surname><given-names>M.</given-names></name><name><surname>Channer</surname><given-names>K. S.</given-names></name></person-group><article-title>An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation</article-title><source><italic>Heart</italic></source><year>1999</year><volume>82</volume><issue>2</issue><fpage>170</fpage><lpage>175</lpage><pub-id pub-id-type="other">2-s2.0-0032782617</pub-id><pub-id pub-id-type="pmid">10409530</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanna</surname><given-names>T.</given-names></name><name><surname>Di Lazzaro</surname><given-names>V.</given-names></name></person-group><article-title>Thromboembolic risk management in paroxysmal atrial fibrillation after brain haemorrhage</article-title><source><italic>International Journal of Stroke</italic></source><year>2011</year><volume>6</volume><issue>1</issue><fpage>92</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1111/j.1747-4949.2010.00548.x</pub-id><pub-id pub-id-type="other">2-s2.0-78650941587</pub-id><pub-id pub-id-type="pmid">21205251</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cain</surname><given-names>M. E.</given-names></name><name><surname>Curtis</surname><given-names>A. B.</given-names></name></person-group><article-title>Rhythm control in atrial fibrillation&#x02014;one setback after another</article-title><source><italic>The New England Journal of Medicine</italic></source><year>2008</year><volume>358</volume><issue>25</issue><fpage>2725</fpage><lpage>2727</lpage><pub-id pub-id-type="other">2-s2.0-45549097433</pub-id><pub-id pub-id-type="doi">10.1056/NEJMe0803289</pub-id><pub-id pub-id-type="pmid">18565866</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname><given-names>D.</given-names></name><name><surname>Talajic</surname><given-names>M.</given-names></name><name><surname>Nattel</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Rhythm control versus rate control for atrial fibrillation and heart failure</article-title><source><italic>The New England Journal of Medicine</italic></source><year>2008</year><volume>358</volume><issue>25</issue><fpage>2667</fpage><lpage>2677</lpage><pub-id pub-id-type="pmid">18565859</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawin</surname><given-names>C. T.</given-names></name><name><surname>Geller</surname><given-names>A.</given-names></name><name><surname>Wolf</surname><given-names>P. A.</given-names></name><etal/></person-group><article-title>Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons</article-title><source><italic>The New England Journal of Medicine</italic></source><year>1994</year><volume>331</volume><issue>19</issue><fpage>1249</fpage><lpage>1252</lpage><pub-id pub-id-type="doi">10.1056/NEJM199411103311901</pub-id><pub-id pub-id-type="other">2-s2.0-0027997922</pub-id><pub-id pub-id-type="pmid">7935681</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>I.</given-names></name><name><surname>Danzi</surname><given-names>S.</given-names></name></person-group><article-title>Thyroid disease and the heart</article-title><source><italic>Circulation</italic></source><year>2007</year><volume>116</volume><issue>15</issue><fpage>1725</fpage><lpage>1735</lpage><pub-id pub-id-type="other">2-s2.0-35148895083</pub-id><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.678326</pub-id><pub-id pub-id-type="pmid">17923583</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bielecka-Dabrowa</surname><given-names>A.</given-names></name><name><surname>Mikhailidis</surname><given-names>D. P.</given-names></name><name><surname>Rysz</surname><given-names>J.</given-names></name><name><surname>Banach</surname><given-names>M.</given-names></name></person-group><article-title>The mechanisms of atrial fibrillation in hyperthyroidism</article-title><source><italic>Thyroid Research</italic></source><year>2009</year><volume>2</volume><issue>1, article 4</issue><pub-id pub-id-type="doi">10.1186/1756-6614-2-4</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wustmann</surname><given-names>K.</given-names></name><name><surname>Kucera</surname><given-names>J. P.</given-names></name><name><surname>Zanchi</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Activation of electrical triggers of atrial fibrillation in hyperthyroidism</article-title><source><italic>The Journal of Clinical Endocrinology &#x00026; Metabolism</italic></source><year>2008</year><volume>93</volume><issue>6</issue><fpage>2104</fpage><lpage>2108</lpage><pub-id pub-id-type="doi">10.1210/jc.2008-0092</pub-id><pub-id pub-id-type="other">2-s2.0-45149112437</pub-id><pub-id pub-id-type="pmid">18349059</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komiya</surname><given-names>N.</given-names></name><name><surname>Isomoto</surname><given-names>S.</given-names></name><name><surname>Nakao</surname><given-names>K.</given-names></name><name><surname>Hayano</surname><given-names>M.</given-names></name><name><surname>Yano</surname><given-names>K.</given-names></name></person-group><article-title>Electrophysiological abnormalities of the atrial muscle in patients with paroxysmal atrial fibrillation associated with hyperthyroidism</article-title><source><italic>Clinical Endocrinology</italic></source><year>2002</year><volume>56</volume><issue>1</issue><fpage>39</fpage><lpage>44</lpage><pub-id pub-id-type="other">2-s2.0-0036156032</pub-id><pub-id pub-id-type="doi">10.1046/j.0300-0664.2001.01459.x</pub-id><pub-id pub-id-type="pmid">11849245</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burashnikov</surname><given-names>A.</given-names></name><name><surname>Petroski</surname><given-names>A.</given-names></name><name><surname>Hu</surname><given-names>D.</given-names></name><name><surname>Barajas-Martinez</surname><given-names>H.</given-names></name><name><surname>Antzelevitch</surname><given-names>C.</given-names></name></person-group><article-title>Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation</article-title><source><italic>Heart Rhythm</italic></source><year>2012</year><volume>9</volume><issue>1</issue><fpage>125</fpage><lpage>131</lpage><pub-id pub-id-type="other">2-s2.0-84555213111</pub-id><pub-id pub-id-type="doi">10.1016/j.hrthm.2011.08.027</pub-id><pub-id pub-id-type="pmid">21884675</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalifa</surname><given-names>J.</given-names></name><name><surname>Avula</surname><given-names>U. M. R.</given-names></name></person-group><article-title>The Chinese herb extract Wenxin Keli: atrial selectivity from the Far East</article-title><source><italic>Heart Rhythm</italic></source><year>2012</year><volume>9</volume><issue>1</issue><fpage>132</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1016/j.hrthm.2011.11.030</pub-id><pub-id pub-id-type="other">2-s2.0-84555202474</pub-id><pub-id pub-id-type="pmid">22116050</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Nie</surname><given-names>S.</given-names></name><name><surname>Gao</surname><given-names>H.</given-names></name><etal/></person-group><article-title>The effects of Wenxin Keli on P-wave dispersion and maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation: a meta-analysis of randomized controlled trials</article-title><source><italic>Evidence-Based Complementary and Alternative Medicine</italic></source><year>2013</year><volume>2013</volume><fpage>9</fpage><pub-id pub-id-type="publisher-id">245958</pub-id><pub-id pub-id-type="doi">10.1155/2013/245958</pub-id><pub-id pub-id-type="other">2-s2.0-84893749055</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Gu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Huang</surname><given-names>C.</given-names></name></person-group><article-title>Wenxin Keli attenuates ischemia-induced ventricular arrhythmias in rats: involvement of L-type calcium and transient outward potassium currents</article-title><source><italic>Molecular Medicine Reports</italic></source><year>2013</year><volume>7</volume><issue>2</issue><fpage>519</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.3892/mmr.2012.1195</pub-id><pub-id pub-id-type="other">2-s2.0-84873818091</pub-id><pub-id pub-id-type="pmid">23174802</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>X.</given-names></name><name><surname>Guo</surname><given-names>D.</given-names></name><name><surname>Sun</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Wenxin Keli suppresses ventricular triggered arrhythmias via selective inhibition of late sodium current</article-title><source><italic>Pacing and Clinical Electrophysiology</italic></source><year>2013</year><volume>36</volume><issue>6</issue><fpage>732</fpage><lpage>740</lpage><pub-id pub-id-type="other">2-s2.0-84878577289</pub-id><pub-id pub-id-type="doi">10.1111/pace.12109</pub-id><pub-id pub-id-type="pmid">23438075</pub-id></element-citation></ref><ref id="B20"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minoura</surname><given-names>Y.</given-names></name><name><surname>Panama</surname><given-names>B. K.</given-names></name><name><surname>Nesterenko</surname><given-names>V. V.</given-names></name><etal/></person-group><article-title>Effect of Wenxin Keli and quinidine to suppress arrhythmogenesis in an experimental model of Brugada syndrome</article-title><source><italic>Heart Rhythm</italic></source><year>2013</year><volume>10</volume><issue>7</issue><fpage>1054</fpage><lpage>1062</lpage><pub-id pub-id-type="doi">10.1016/j.hrthm.2013.03.011</pub-id><pub-id pub-id-type="other">2-s2.0-84879502996</pub-id><pub-id pub-id-type="pmid">23499631</pub-id></element-citation></ref><ref id="B21"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>R. F.</given-names></name><name><surname>Tan</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>G. Z.</given-names></name><name><surname>Meng</surname><given-names>Z. W.</given-names></name><name><surname>Zheng</surname><given-names>W.</given-names></name></person-group><article-title>A comparative study of influential factors correlating with early and late hypothyroidism after 131I therapy for graves' disease</article-title><source><italic>Chinese Medical Journal</italic></source><year>2010</year><volume>123</volume><issue>12</issue><fpage>1528</fpage><lpage>1532</lpage><pub-id pub-id-type="doi">10.3760/cma.j.issn.0366-6999.2010.12.009</pub-id><pub-id pub-id-type="other">2-s2.0-79851499869</pub-id><pub-id pub-id-type="pmid">20819506</pub-id></element-citation></ref><ref id="B22"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>W.</given-names></name><name><surname>Jian</surname><given-names>T.</given-names></name><name><surname>Guizhi</surname><given-names>Z.</given-names></name><name><surname>Zhaowei</surname><given-names>M.</given-names></name><name><surname>Renfei</surname><given-names>W.</given-names></name></person-group><article-title>Analysis of 131I therapy and correlation factors of Graves' disease patients: a 4-year retrospective study</article-title><source><italic>Nuclear Medicine Communications</italic></source><year>2012</year><volume>33</volume><issue>1</issue><fpage>97</fpage><lpage>101</lpage><pub-id pub-id-type="other">2-s2.0-82555187854</pub-id><pub-id pub-id-type="doi">10.1097/MNM.0b013e32834d3bb9</pub-id><pub-id pub-id-type="pmid">22008631</pub-id></element-citation></ref><ref id="B23"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakazawa</surname><given-names>H.</given-names></name><name><surname>Lythall</surname><given-names>D. A.</given-names></name><name><surname>Noh</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Is there a place for the late cardioversion of atrial fibrillation? A long-term follow-up study of patients with post-thyrotoxic atrial fibrillation</article-title><source><italic>European Heart Journal</italic></source><year>2000</year><volume>21</volume><issue>4</issue><fpage>327</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1053/euhj.1999.1956</pub-id><pub-id pub-id-type="other">2-s2.0-0034099271</pub-id><pub-id pub-id-type="pmid">10653681</pub-id></element-citation></ref><ref id="B24"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Z. H.</given-names></name><name><surname>Ma</surname><given-names>L. L.</given-names></name><name><surname>Wang</surname><given-names>L. X.</given-names></name></person-group><article-title>Risk factors for persistent atrial fibrillation following successful hyperthyroidism treatment with radioiodine therapy</article-title><source><italic>Internal Medicine</italic></source><year>2011</year><volume>50</volume><issue>24</issue><fpage>2947</fpage><lpage>2951</lpage><pub-id pub-id-type="doi">10.2169/internalmedicine.50.6135</pub-id><pub-id pub-id-type="other">2-s2.0-83755194681</pub-id><pub-id pub-id-type="pmid">22185984</pub-id></element-citation></ref><ref id="B25"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kunii</surname><given-names>Y.</given-names></name><name><surname>Uruno</surname><given-names>T.</given-names></name><name><surname>Matsumoto</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Pharmacological conversion of atrial fibrillation in the patients of Graves' disease</article-title><source><italic>Tokai Journal of Experimental and Clinical Medicine</italic></source><year>2012</year><volume>37</volume><issue>4</issue><fpage>107</fpage><lpage>112</lpage><pub-id pub-id-type="other">2-s2.0-84871569823</pub-id><pub-id pub-id-type="pmid">23238902</pub-id></element-citation></ref><ref id="B26"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>E.</given-names></name><name><surname>Tan</surname><given-names>M.</given-names></name><name><surname>Xin</surname><given-names>J.</given-names></name><name><surname>Sudarsanam</surname><given-names>S.</given-names></name><name><surname>Johnson</surname><given-names>D. E.</given-names></name></person-group><article-title>Interactions between traditional Chinese medicines and Western therapeutics</article-title><source><italic>Current Opinion in Drug Discovery &#x00026; Development</italic></source><year>2010</year><volume>13</volume><issue>1</issue><fpage>50</fpage><lpage>65</lpage><pub-id pub-id-type="other">2-s2.0-73849123558</pub-id><pub-id pub-id-type="pmid">20047146</pub-id></element-citation></ref><ref id="B27"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X. J.</given-names></name><name><surname>Zhang</surname><given-names>H. Y.</given-names></name></person-group><article-title>Western healers in traditional Chinese medicine</article-title><source><italic>EMBO Reports</italic></source><year>2008</year><volume>9</volume><issue>2</issue><fpage>112</fpage><lpage>113</lpage><pub-id pub-id-type="other">2-s2.0-38949094913</pub-id><pub-id pub-id-type="doi">10.1038/sj.embor.7401166</pub-id><pub-id pub-id-type="pmid">18246100</pub-id></element-citation></ref><ref id="B28"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>J. D.</given-names></name></person-group><article-title>Clinical observation of Wenxin Keli for the treatment of paroxysmal atrial ibrillation</article-title><source><italic>Chinese Journal of Information on Traditional Chinese Medicine</italic></source><year>2007</year><volume>14</volume><issue>8</issue><fpage>55</fpage><lpage>56</lpage></element-citation></ref><ref id="B29"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>Y.</given-names></name><name><surname>Xing</surname><given-names>L. F.</given-names></name><name><surname>Li</surname><given-names>B. M.</given-names></name><name><surname>Tong</surname><given-names>C. J.</given-names></name></person-group><article-title>Effect of Wenxin particle combine with fluvastatin on atrial remodelling in essential hypertension patients with atrial fibrillation</article-title><source><italic>Chinese Journal of Difficult and Complicated Cases</italic></source><year>2010</year><volume>9</volume><issue>8</issue><fpage>566</fpage><lpage>568</lpage></element-citation></ref><ref id="B30"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>S. R.</given-names></name></person-group><article-title>The effect of Wenxin Keli on P wave dispersion and the treatment for the paroxysmal atrial fibrillation</article-title><source><italic>Chinese Journal of Modern Drug Application</italic></source><year>2011</year><volume>5</volume><issue>12</issue><fpage>92</fpage><lpage>93</lpage></element-citation></ref><ref id="B31"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>N.</given-names></name><name><surname>Lin</surname><given-names>D.</given-names></name><name><surname>Lin</surname><given-names>P.</given-names></name></person-group><article-title>Wenxin granule and low dose amiodarone in treating 60 cases of senile paroxysmal atrial fibrillation</article-title><source><italic>Fujian Journal of Traditional Chinese Medicine</italic></source><year>2010</year><volume>41</volume><issue>3</issue><fpage>7</fpage><lpage>8</lpage></element-citation></ref><ref id="B32"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C. J.</given-names></name></person-group><article-title>Effect of Wenxin granule treatment for paroxysmal atrial fibrillation patients</article-title><source><italic>Practical Pharmacy and Clinical Remedies</italic></source><year>2012</year><volume>15</volume><issue>11</issue><fpage>737</fpage><lpage>739</lpage></element-citation></ref><ref id="B33"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>M. L.</given-names></name><name><surname>Jing</surname><given-names>S. X.</given-names></name><name><surname>Zhang</surname><given-names>H. Y.</given-names></name></person-group><article-title>The effect of Buchangwenxin particle on dispersion of P wave in elder patients with diastolic cardiac dysfunction and paroxysmal atrial fibrillation</article-title><source><italic>Chinese Journal of Primary Medicine and Pharmacy</italic></source><year>2011</year><volume>18</volume><issue>20</issue><fpage>2756</fpage><lpage>2758</lpage></element-citation></ref><ref id="B34"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z. M.</given-names></name><name><surname>Bai</surname><given-names>P.</given-names></name><name><surname>Lin</surname><given-names>J. Z.</given-names></name></person-group><article-title>Wenxin Keli combined with ethylamine iodine skin ketone in treating senile hypertension paroxysmal atrial fibrillation</article-title><source><italic>Chinese Journal of Hypertension</italic></source><year>2008</year><volume>16</volume><issue>12</issue><fpage>1134</fpage><lpage>1135</lpage></element-citation></ref><ref id="B35"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>J. L.</given-names></name><name><surname>Dong</surname><given-names>Y.</given-names></name><name><surname>Xing</surname><given-names>L. F.</given-names></name></person-group><article-title>The maintenance of sinus rhythm in patients with elderly hypertensive paroxysmal atrial fibrillation and the intervention of Wenxin Keli combined with fluvastatin</article-title><source><italic>Hebei Medical Journal</italic></source><year>2010</year><volume>32</volume><issue>24</issue><fpage>3483</fpage><lpage>3484</lpage></element-citation></ref><ref id="B36"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>Y.-J.</given-names></name><name><surname>Zhang</surname><given-names>Y.-M.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>S.-Y.</given-names></name><name><surname>Cui</surname><given-names>H.-D.</given-names></name></person-group><article-title>Effect of Wenxin-Keli combined with amiodarone on dispersion of P wave and C-reactive protein in patients with paroxysmal atrial fibrillation</article-title><source><italic>Chinese Journal of New Drugs</italic></source><year>2011</year><volume>20</volume><issue>15</issue><fpage>1432</fpage><lpage>1434</lpage><pub-id pub-id-type="other">2-s2.0-84859480410</pub-id></element-citation></ref><ref id="B37"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>B.</given-names></name></person-group><article-title>Clinical observation of Wenxin Keli combined with valsartan on the maintenance of sinus rhythm in patients with hypertension with paroxysmal atrial fibrillation</article-title><source><italic>Chinese Community Doctors</italic></source><year>2012</year><volume>14</volume><issue>7</issue><fpage>p. 54</fpage></element-citation></ref><ref id="B38"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F. C.</given-names></name><name><surname>Tong</surname><given-names>J. J.</given-names></name><name><surname>Hao</surname><given-names>W.</given-names></name><name><surname>Ma</surname><given-names>Z.</given-names></name></person-group><article-title>The effect of Wenxin Keli combined with amiodarone for the treatment of paroxysmal atrial fibrillation in 32 cases</article-title><source><italic>Shanxi Journal of Traditional Chinese Medicine</italic></source><year>2008</year><volume>29</volume><issue>7</issue><fpage>839</fpage><lpage>840</lpage></element-citation></ref><ref id="B39"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>P.-Y.</given-names></name><name><surname>Shen</surname><given-names>S.-H.</given-names></name></person-group><article-title>Effect of combination of Chinese and Western medicines on sinus rhythm maintenance in patients with auricular fibrillation after conversion</article-title><source><italic>Chinese Journal of Integrated Traditional and Western Medicine</italic></source><year>2006</year><volume>26</volume><issue>7</issue><fpage>644</fpage><lpage>646</lpage><pub-id pub-id-type="other">2-s2.0-38049082159</pub-id><pub-id pub-id-type="pmid">16983923</pub-id></element-citation></ref><ref id="B40"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>S. Z.</given-names></name></person-group><article-title>The study of prevention and curative effect of the Valsartan and Wenxin Keli on the paroxysmal atrial fibrillation</article-title><source><italic>Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine</italic></source><year>2008</year><volume>8</volume><issue>4</issue><fpage>6</fpage><lpage>7</lpage></element-citation></ref><ref id="B41"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Q. H.</given-names></name><name><surname>Zhang</surname><given-names>X. B.</given-names></name></person-group><article-title>The effect of Wenxin Keli combined with amiodarone on the maintenance of sinus rhythm and serum MMP-9 in patients with paroxysmal atrial fibrillation</article-title><source><italic>Guiding Journal of Traditional Chinese Medicine and Pharmacology</italic></source><year>2013</year><volume>19</volume><issue>2</issue><fpage>36</fpage><lpage>37</lpage></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Participant flow chart. Initially, in the first stage of the study (a), 180 eligible hyperthyroidism patients with paroxysmal atrial fibrillation were randomized into either Wenxin Keli (91 cases) or sotalol (89 cases) treatment for sinus rhythm restoration. At the end of the first stage intervention, 83/91 cases and 80/89 cases were reverted to sinus rhythm, respectively. There were 8/91 cases and 9/89 cases who did not restore sinus rhythm. These 17 patients (still with atrial fibrillation) were not eligible for the second part of the study, and they were dropped out. In the second stage of the study (b), all sinus rhythm reverted patients (163 cases) were randomized into one of the following three groups: WK (54 cases), sotalol (54 cases), and control (55 cases) groups. The purpose is to observe drug's sinus rhythm maintenance effect. At the end of the second stage intervention, 1/54 cases, 2/54 cases, and 9/55 cases had recurrent paroxysmal atrial fibrillation, respectively.</p></caption><graphic xlink:href="ECAM2015-101904.001"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>A typical case of successful sinus rhythm restoration from paroxysmal atrial fibrillation. A 64-year-old male patient was diagnosed with Graves' disease for eight years. He had paroxysmal atrial fibrillation for three years (a). He was given 6 mCi of <sup>131</sup>I for the treatment of Graves' disease. And Wenxin Keli (18&#x02009;g tid) was prescribed during and after the <sup>131</sup>I treatment. Baseline free triiodothyronine, free thyroxine, and thyroid stimulating hormone were 21.46&#x02009;pmol/L, 104.8&#x02009;pmol/L, and 0.011&#x02009;<italic>&#x003bc;</italic>IU/mL, respectively. One month later, when sinus rhythm was restored (b), free triiodothyronine, free thyroxine, and thyroid stimulating hormone were 3.35&#x02009;pmol/L, 12.89&#x02009;pmol/L, and 4.52&#x02009;<italic>&#x003bc;</italic>IU/mL, respectively. At the three-month end-point of the first investigation, thyroid hormones were still normal. After entering the second investigation, Wenxin Keli (9&#x02009;g tid) was prescribed during the follow-up. His thyroid function maintained normal level, and his heart rhythm maintained sinus rhythm during the rest of the study.</p></caption><graphic xlink:href="ECAM2015-101904.002"/></fig><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>The cumulative recurrent rate of paroxysmal atrial fibrillation during the follow-up in different groups. In the second part of the study, we randomly assigned the successfully sinus rhythm reverted patients into one of the following three groups: 54 cases were given Wenxin Keli (9&#x02009;g tid), 54 cases were given sotalol (40&#x02009;mg bid), and 55 cases served as control. Kaplan-Meier analysis by Log-Rank&#x02009;<italic>&#x003c7;</italic>
<sup><italic>2</italic></sup> test was used to determine the cumulative recurrent rate of paroxysmal atrial fibrillation in different groups during the one-year-long follow-up. Vertical axle was PAF recurrence free rate and horizontal axle was the follow-up time (WK = Wenxin Keli, PAF = paroxysmal atrial fibrillation).</p></caption><graphic xlink:href="ECAM2015-101904.003"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline information of all participants.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Parameters</th><th align="center" rowspan="1" colspan="1">WK<sup>*</sup> treatment (91 cases)</th><th align="center" rowspan="1" colspan="1">Sotalol treatment (89 cases)</th><th align="center" rowspan="1" colspan="1">
<italic>t</italic> value (<italic>P</italic> value)<sup>**</sup>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Hyperthyroidism history (years)</td><td align="center" rowspan="1" colspan="1">8.374 &#x000b1; 2.619</td><td align="center" rowspan="1" colspan="1">8.551 &#x000b1; 2.680</td><td align="center" rowspan="1" colspan="1">0.448 (0.655)</td></tr><tr><td align="left" rowspan="1" colspan="1">PAF<sup>*</sup> history (years)</td><td align="center" rowspan="1" colspan="1">4.099 &#x000b1; 1.599</td><td align="center" rowspan="1" colspan="1">4.213 &#x000b1; 1.675</td><td align="center" rowspan="1" colspan="1">0.469 (0.639)</td></tr><tr><td align="left" rowspan="1" colspan="1">FT3<sup>*</sup> (pmol/L)</td><td align="center" rowspan="1" colspan="1">24.613 &#x000b1; 5.059</td><td align="center" rowspan="1" colspan="1">24.405 &#x000b1; 5.006</td><td align="center" rowspan="1" colspan="1">&#x02212;0.278 (0.781)</td></tr><tr><td align="left" rowspan="1" colspan="1">FT4<sup>*</sup> (pmol/L)</td><td align="center" rowspan="1" colspan="1">118.697 &#x000b1; 29.213</td><td align="center" rowspan="1" colspan="1">116.132 &#x000b1; 28.266</td><td align="center" rowspan="1" colspan="1">&#x02212;0.598 (0.550)</td></tr><tr><td align="left" rowspan="1" colspan="1">TSH<sup>*</sup> (<italic>&#x003bc;</italic>IU/mL)</td><td align="center" rowspan="1" colspan="1">0.007 &#x000b1; 0.010</td><td align="center" rowspan="1" colspan="1">0.009 &#x000b1; 0.015</td><td align="center" rowspan="1" colspan="1">1.191 (0.235)</td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>&#x02217;</sup>WK: Wenxin Keli, PAF: paroxysmal atrial fibrillation, FT3: free triiodothyronine, FT4: free thyroxine, and TSH: thyroid stimulating hormone; <sup>**</sup>analyzed by independent samples <italic>t</italic>-test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Case number distribution of patients after WK<sup>*</sup> or sotalol treatments in the first investigation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Groups (case number)</th><th align="center" colspan="2" rowspan="1">
Male</th><th align="center" colspan="2" rowspan="1">
Female</th></tr><tr><th align="center" rowspan="1" colspan="1">Total number</th><th align="center" rowspan="1" colspan="1">SR<sup>*</sup> restored number</th><th align="center" rowspan="1" colspan="1">Total number</th><th align="center" rowspan="1" colspan="1">SR<sup>*</sup> restored number</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">WK<sup>*</sup> treatment (91 cases)</td><td align="center" rowspan="1" colspan="1">49</td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">38</td></tr><tr><td align="left" rowspan="1" colspan="1">Sotalol treatment (89 cases)</td><td align="center" rowspan="1" colspan="1">49</td><td align="center" rowspan="1" colspan="1">44</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">36</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x003c7;</italic>
<sup>2</sup> value (<italic>P</italic> value)<sub>(WK)&#x02009;:&#x02009;(sotalol)</sub>
<sup>&#x02217;&#x02217;</sup>
</td><td align="center" colspan="4" rowspan="1">0.092 (0.762)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x003c7;</italic>
<sup>2</sup> value (<italic>P</italic> value)<sub>(male)&#x02009;:&#x02009;(female)</sub>
<sup>&#x02217;&#x02217;</sup>
</td><td align="center" colspan="4" rowspan="1">0.017 (0.896)</td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>&#x02217;</sup>WK: Wenxin Keli; SR: sinus rhythm; <sup>**</sup>analyzed by <italic>&#x003c7;</italic>
<sup>2</sup> test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Comparisons of thyroid hormones in patients before and after WK<sup>*</sup> or sotalol treatments in the first investigation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" colspan="4" rowspan="1">Before treatments</th></tr><tr><th align="left" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">WK<sup>*</sup> treatment (91 cases)</th><th align="center" rowspan="1" colspan="1">Sotalol treatment (89 cases)</th><th align="center" rowspan="1" colspan="1">
<italic>t</italic> value (<italic>P</italic> value)<sup>**</sup>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">FT3<sup>*</sup> (pmol/L)</td><td align="center" rowspan="1" colspan="1">24.613 &#x000b1; 5.059</td><td align="center" rowspan="1" colspan="1">24.405 &#x000b1; 5.006</td><td align="center" rowspan="1" colspan="1">&#x02212;0.278 (0.781)</td></tr><tr><td align="left" rowspan="1" colspan="1">FT4<sup>*</sup> (pmol/L)</td><td align="center" rowspan="1" colspan="1">118.697 &#x000b1; 29.213</td><td align="center" rowspan="1" colspan="1">116.132 &#x000b1; 28.266</td><td align="center" rowspan="1" colspan="1">&#x02212;0.598 (0.550)</td></tr><tr><td align="left" rowspan="1" colspan="1">TSH<sup>*</sup> (<italic>&#x003bc;</italic>IU/mL)</td><td align="center" rowspan="1" colspan="1">0.007 &#x000b1; 0.010</td><td align="center" rowspan="1" colspan="1">0.009 &#x000b1; 0.147</td><td align="center" rowspan="1" colspan="1">1.191 (0.235)</td></tr><tr><td align="center" colspan="4" rowspan="1">
<hr/>
</td></tr><tr><td align="center" colspan="4" rowspan="1">Three months after treatments</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">WK<sup>*</sup> treatment (91 cases)</td><td align="center" rowspan="1" colspan="1">Sotalol treatment (89 cases)</td><td align="center" rowspan="1" colspan="1">
<italic>t</italic> value (<italic>P</italic> value)<sup>**</sup>
</td></tr><tr><td align="center" colspan="4" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">FT3<sup>*</sup> (pmol/L)</td><td align="center" rowspan="1" colspan="1">6.495 &#x000b1; 3.713</td><td align="center" rowspan="1" colspan="1">6.596 &#x000b1; 3.740</td><td align="center" rowspan="1" colspan="1">0.182 (0.855)</td></tr><tr><td align="left" rowspan="1" colspan="1">FT4<sup>*</sup> (pmol/L)</td><td align="center" rowspan="1" colspan="1">21.447 &#x000b1; 11.727</td><td align="center" rowspan="1" colspan="1">21.655 &#x000b1; 10.612</td><td align="center" rowspan="1" colspan="1">0.125 (0.901)</td></tr><tr><td align="left" rowspan="1" colspan="1">TSH<sup>*</sup> (<italic>&#x003bc;</italic>IU/mL)</td><td align="center" rowspan="1" colspan="1">6.210 &#x000b1; 10.002</td><td align="center" rowspan="1" colspan="1">5.752 &#x000b1; 8.915</td><td align="center" rowspan="1" colspan="1">&#x02212;0.324 (0.746)</td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>&#x02217;</sup>WK: Wenxin Keli, FT3: free triiodothyronine, FT4: free thyroxine, and TSH: thyroid stimulating hormone; <sup>**</sup>analyzed by independent samples <italic>t</italic>-test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Case number distribution of patients after <sup>131</sup>I or ATD<sup>*</sup> treatments in the first investigation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Groups (case number)</th><th align="center" colspan="2" rowspan="1">
Male</th><th align="center" colspan="2" rowspan="1">
Female</th></tr><tr><th align="center" rowspan="1" colspan="1">Total number</th><th align="center" rowspan="1" colspan="1">SR<sup>*</sup> restored number</th><th align="center" rowspan="1" colspan="1">Total number</th><th align="center" rowspan="1" colspan="1">SR<sup>*</sup> restored number</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<sup>131</sup>I treatment (90 cases)</td><td align="center" rowspan="1" colspan="1">49</td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1">41</td><td align="center" rowspan="1" colspan="1">39</td></tr><tr><td align="left" rowspan="1" colspan="1">ATD<sup>*</sup> treatment (90 cases)</td><td align="center" rowspan="1" colspan="1">49</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">41</td><td align="center" rowspan="1" colspan="1">35</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x003c7;</italic>
<sup>2</sup> value (<italic>P</italic> value)<sub>(<sup>131</sup>I)&#x02009;:&#x02009;(ATD)</sub>
<sup>&#x02217;&#x02217;</sup>
</td><td align="center" colspan="4" rowspan="1">5.262 (0.022)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x003c7;</italic>
<sup>2</sup> value (<italic>P</italic> value)<sub>(male)&#x02009;:&#x02009;(female)</sub>
<sup>&#x02217;&#x02217;</sup>
</td><td align="center" colspan="4" rowspan="1">0.017 (0.896)</td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>&#x02217;</sup>ATD: antithyroid drugs; SR: sinus rhythm; <sup>**</sup>analyzed by <italic>&#x003c7;</italic>
<sup>2</sup> test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab5" orientation="portrait" position="float"><label>Table 5</label><caption><p>Comparisons of thyroid hormones in patients before and after <sup>131</sup>I or ATD<sup>*</sup> treatments in the first investigation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" colspan="4" rowspan="1">Before treatments</th></tr><tr><th align="left" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">
<sup>131</sup>I treatment (90 cases)</th><th align="center" rowspan="1" colspan="1">ATD<sup>*</sup> treatment (90 cases)</th><th align="center" rowspan="1" colspan="1">
<italic>t</italic> value (<italic>P</italic> value)<sup>**</sup>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">FT3<sup>*</sup> (pmol/L)</td><td align="center" rowspan="1" colspan="1">24.056 &#x000b1; 5.321</td><td align="center" rowspan="1" colspan="1">24.964 &#x000b1; 4.685</td><td align="center" rowspan="1" colspan="1">1.215 (0.226)</td></tr><tr><td align="left" rowspan="1" colspan="1">FT4<sup>*</sup> (pmol/L)</td><td align="center" rowspan="1" colspan="1">117.633 &#x000b1; 29.225</td><td align="center" rowspan="1" colspan="1">117.225 &#x000b1; 28.322</td><td align="center" rowspan="1" colspan="1">&#x02212;0.095 (0.924)</td></tr><tr><td align="left" rowspan="1" colspan="1">TSH<sup>*</sup> (<italic>&#x003bc;</italic>IU/mL)</td><td align="center" rowspan="1" colspan="1">0.007 &#x000b1; 0.011</td><td align="center" rowspan="1" colspan="1">0.009 &#x000b1; 0.014</td><td align="center" rowspan="1" colspan="1">0.757 (0.450)</td></tr><tr><td align="center" colspan="4" rowspan="1">
<hr/>
</td></tr><tr><td align="center" colspan="4" rowspan="1">Three months after treatments</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">
<sup>131</sup>I treatment (90 cases)</td><td align="center" rowspan="1" colspan="1">ATD<sup>*</sup> treatment (90 cases)</td><td align="center" rowspan="1" colspan="1">
<italic>t</italic> value (<italic>P</italic> value)<sup>**</sup>
</td></tr><tr><td align="center" colspan="4" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">FT3<sup>*</sup> (pmol/L)</td><td align="center" rowspan="1" colspan="1">5.837 &#x000b1; 2.830</td><td align="center" rowspan="1" colspan="1">7.252 &#x000b1; 4.330</td><td align="center" rowspan="1" colspan="1">2.595 (0.010)</td></tr><tr><td align="left" rowspan="1" colspan="1">FT4<sup>*</sup> (pmol/L)</td><td align="center" rowspan="1" colspan="1">19.378 &#x000b1; 8.292</td><td align="center" rowspan="1" colspan="1">23.722 &#x000b1; 13.120</td><td align="center" rowspan="1" colspan="1">2.655 (0.009)</td></tr><tr><td align="left" rowspan="1" colspan="1">TSH<sup>*</sup> (<italic>&#x003bc;</italic>IU/mL)</td><td align="center" rowspan="1" colspan="1">6.427 &#x000b1; 9.702</td><td align="center" rowspan="1" colspan="1">5.539 &#x000b1; 9.237</td><td align="center" rowspan="1" colspan="1">&#x02212;0.629 (0.530)</td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>&#x02217;</sup>ATD: antithyroid drugs, FT3: free triiodothyronine, FT4: free thyroxine, and TSH: thyroid stimulating hormone; <sup>**</sup>analyzed by independent samples <italic>t</italic>-test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab6" orientation="portrait" position="float"><label>Table 6</label><caption><p>Comparisons of thyroid hormones at any follow-up time-points in the second investigation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" colspan="5" rowspan="1">Baseline</th></tr><tr><th align="left" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">WK<sup>*</sup> treatment (54 cases)</th><th align="center" rowspan="1" colspan="1">Sotalol treatment (54 cases)</th><th align="center" rowspan="1" colspan="1">Control (55 cases)</th><th align="center" rowspan="1" colspan="1">
<italic>F</italic> value (<italic>P</italic> value)<sup>**</sup>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">FT3<sup>*</sup> (pmol/L)</td><td align="center" rowspan="1" colspan="1">5.532 &#x000b1; 2.372</td><td align="center" rowspan="1" colspan="1">5.752 &#x000b1; 2.608</td><td align="center" rowspan="1" colspan="1">5.680 &#x000b1; 2.486</td><td align="center" rowspan="1" colspan="1">0.110 (0.896)</td></tr><tr><td align="left" rowspan="1" colspan="1">FT4<sup>*</sup> (pmol/L)</td><td align="center" rowspan="1" colspan="1">18.469 &#x000b1; 7.182</td><td align="center" rowspan="1" colspan="1">19.351 &#x000b1; 7.577</td><td align="center" rowspan="1" colspan="1">19.046 &#x000b1; 7.576</td><td align="center" rowspan="1" colspan="1">0.195 (0.823)</td></tr><tr><td align="left" rowspan="1" colspan="1">TSH<sup>*</sup> (<italic>&#x003bc;</italic>IU/mL)</td><td align="center" rowspan="1" colspan="1">7.126 &#x000b1; 10.449</td><td align="center" rowspan="1" colspan="1">5.859 &#x000b1; 8.668</td><td align="center" rowspan="1" colspan="1">6.832 &#x000b1; 10.110</td><td align="center" rowspan="1" colspan="1">0.249 (0.780)</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="center" colspan="5" rowspan="1">Three months</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">WK<sup>*</sup> treatment (54 cases)</td><td align="center" rowspan="1" colspan="1">Sotalol treatment (54 cases)</td><td align="center" rowspan="1" colspan="1">Control (55 cases)</td><td align="center" rowspan="1" colspan="1">
<italic>F</italic> value (<italic>P</italic> value)<sup>**</sup>
</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">FT3<sup>*</sup> (pmol/L)</td><td align="center" rowspan="1" colspan="1">5.035 &#x000b1; 0.934</td><td align="center" rowspan="1" colspan="1">5.129 &#x000b1; 0.908</td><td align="center" rowspan="1" colspan="1">5.098 &#x000b1; 0.965</td><td align="center" rowspan="1" colspan="1">0.140 (0.870)</td></tr><tr><td align="left" rowspan="1" colspan="1">FT4<sup>*</sup> (pmol/L)</td><td align="center" rowspan="1" colspan="1">15.664 &#x000b1; 3.112</td><td align="center" rowspan="1" colspan="1">16.061 &#x000b1; 3.336</td><td align="center" rowspan="1" colspan="1">15.994 &#x000b1; 3.465</td><td align="center" rowspan="1" colspan="1">0.222 (0.801)</td></tr><tr><td align="left" rowspan="1" colspan="1">TSH<sup>*</sup> (<italic>&#x003bc;</italic>IU/mL)</td><td align="center" rowspan="1" colspan="1">4.683 &#x000b1; 4.211</td><td align="center" rowspan="1" colspan="1">4.083 &#x000b1; 3.456</td><td align="center" rowspan="1" colspan="1">4.352 &#x000b1; 3.885</td><td align="center" rowspan="1" colspan="1">0.326 (0.722)</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="center" colspan="5" rowspan="1">Six months</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">WK<sup>*</sup> treatment (54 cases)</td><td align="center" rowspan="1" colspan="1">Sotalol treatment (54 cases)</td><td align="center" rowspan="1" colspan="1">Control (55 cases)</td><td align="center" rowspan="1" colspan="1">
<italic>F</italic> value (<italic>P</italic> value)<sup>**</sup>
</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">FT3<sup>*</sup> (pmol/L)</td><td align="center" rowspan="1" colspan="1">5.257 &#x000b1; 0.930</td><td align="center" rowspan="1" colspan="1">5.373 &#x000b1; 0.915</td><td align="center" rowspan="1" colspan="1">5.381 &#x000b1; 1.057</td><td align="center" rowspan="1" colspan="1">0.277 (0.758)</td></tr><tr><td align="left" rowspan="1" colspan="1">FT4<sup>*</sup> (pmol/L)</td><td align="center" rowspan="1" colspan="1">16.446 &#x000b1; 3.339</td><td align="center" rowspan="1" colspan="1">16.916 &#x000b1; 3.727</td><td align="center" rowspan="1" colspan="1">16.955 &#x000b1; 4.014</td><td align="center" rowspan="1" colspan="1">0.317 (0.729)</td></tr><tr><td align="left" rowspan="1" colspan="1">TSH<sup>*</sup> (<italic>&#x003bc;</italic>IU/mL)</td><td align="center" rowspan="1" colspan="1">4.032 &#x000b1; 3.492</td><td align="center" rowspan="1" colspan="1">3.567 &#x000b1; 2.885</td><td align="center" rowspan="1" colspan="1">3.756 &#x000b1; 3.202</td><td align="center" rowspan="1" colspan="1">0.288 (0.750)</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="center" colspan="5" rowspan="1">Nine months</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">WK<sup>*</sup> treatment (54 cases)</td><td align="center" rowspan="1" colspan="1">Sotalol treatment (54 cases)</td><td align="center" rowspan="1" colspan="1">Control (55 cases)</td><td align="center" rowspan="1" colspan="1">
<italic>F</italic> value (<italic>P</italic> value)<sup>**</sup>
</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">FT3<sup>*</sup> (pmol/L)</td><td align="center" rowspan="1" colspan="1">5.367 &#x000b1; 0.975</td><td align="center" rowspan="1" colspan="1">5.458 &#x000b1; 0.958</td><td align="center" rowspan="1" colspan="1">5.590 &#x000b1; 1.328</td><td align="center" rowspan="1" colspan="1">0.566 (0.569)</td></tr><tr><td align="left" rowspan="1" colspan="1">FT4<sup>*</sup> (pmol/L)</td><td align="center" rowspan="1" colspan="1">17.184 &#x000b1; 3.208</td><td align="center" rowspan="1" colspan="1">17.760 &#x000b1; 4.131</td><td align="center" rowspan="1" colspan="1">18.084 &#x000b1; 4.833</td><td align="center" rowspan="1" colspan="1">0.668 (0.514)</td></tr><tr><td align="left" rowspan="1" colspan="1">TSH<sup>*</sup> (<italic>&#x003bc;</italic>IU/mL)</td><td align="center" rowspan="1" colspan="1">2.912 &#x000b1; 1.730</td><td align="center" rowspan="1" colspan="1">2.701 &#x000b1; 1.666</td><td align="center" rowspan="1" colspan="1">2.785 &#x000b1; 1.719</td><td align="center" rowspan="1" colspan="1">0.211 (0.810)</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="center" colspan="5" rowspan="1">Twelve months</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">WK<sup>*</sup> treatment (54 cases)</td><td align="center" rowspan="1" colspan="1">Sotalol treatment (54 cases)</td><td align="center" rowspan="1" colspan="1">Control (55 cases)</td><td align="center" rowspan="1" colspan="1">
<italic>F</italic> value (<italic>P</italic> value)<sup>**</sup>
</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">FT3<sup>*</sup> (pmol/L)</td><td align="center" rowspan="1" colspan="1">5.562 &#x000b1; 0.969</td><td align="center" rowspan="1" colspan="1">5.740 &#x000b1; 1.302</td><td align="center" rowspan="1" colspan="1">5.874 &#x000b1; 1.406</td><td align="center" rowspan="1" colspan="1">0.866 (0.422)</td></tr><tr><td align="left" rowspan="1" colspan="1">FT4<sup>*</sup> (pmol/L)</td><td align="center" rowspan="1" colspan="1">17.830 &#x000b1; 3.485</td><td align="center" rowspan="1" colspan="1">18.532 &#x000b1; 5.113</td><td align="center" rowspan="1" colspan="1">18.901 &#x000b1; 5.388</td><td align="center" rowspan="1" colspan="1">0.716 (0.490)</td></tr><tr><td align="left" rowspan="1" colspan="1">TSH<sup>*</sup> (<italic>&#x003bc;</italic>IU/mL)</td><td align="center" rowspan="1" colspan="1">2.519 &#x000b1; 1.420</td><td align="center" rowspan="1" colspan="1">2.388 &#x000b1; 1.423</td><td align="center" rowspan="1" colspan="1">2.409 &#x000b1; 1.488</td><td align="center" rowspan="1" colspan="1">0.129 (0.879)</td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>&#x02217;</sup>WK: Wenxin Keli, FT3: free triiodothyronine, FT4: free thyroxine, and TSH: thyroid stimulating hormone; <sup>**</sup>analyzed by one-way analysis of variance and least significant difference test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab7" orientation="portrait" position="float"><label>Table 7</label><caption><p>Cumulative recurrent PAF<sup>*</sup> at the end of follow-up in the second investigation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Groups (case number)</th><th align="center" colspan="2" rowspan="1">
Male</th><th align="center" colspan="2" rowspan="1">
Female</th></tr><tr><th align="center" rowspan="1" colspan="1">Total number</th><th align="center" rowspan="1" colspan="1">Cumulative recurrent PAF</th><th align="center" rowspan="1" colspan="1">Total number</th><th align="center" rowspan="1" colspan="1">Cumulative recurrent PAF</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">WK<sup>*</sup> treatment (54 cases)</td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Sotalol treatment (54 cases)</td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Control (55 cases)</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">5</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x003c7;</italic>
<sup>2</sup> value (<italic>P</italic> value)<sub>(WK)&#x02009;:&#x02009;(control)</sub>
<sup>&#x02217;&#x02217;</sup>
</td><td align="center" colspan="4" rowspan="1">6.886 (0.009)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x003c7;</italic>
<sup>2</sup> value (<italic>P</italic> value)<sub>(sotalol)&#x02009;:&#x02009;(control)</sub>
<sup>&#x02217;&#x02217;</sup>
</td><td align="center" colspan="4" rowspan="1">4.813 (0.028)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x003c7;</italic>
<sup>2</sup> value (<italic>P</italic> value)<sub>(WK)&#x02009;:&#x02009;(sotalol)</sub>
<sup>&#x02217;&#x02217;</sup>
</td><td align="center" colspan="4" rowspan="1">0.343 (0.558)</td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>&#x02217;</sup>WK: Wenxin Keli; PAF: paroxysmal atrial fibrillation; <sup>**</sup>analyzed by <italic>&#x003c7;</italic>
<sup>2</sup> test.</p></fn></table-wrap-foot></table-wrap></floats-group></article>